Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats

Popik Piotr, Hogendorf Adam, Bugno Ryszard, Khoo Shaun Yon-Seng, Zajdel Pawel, Malikowska-Racia Natalia, Nikiforuk Agnieszka, Golebiowska Joanna

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (56)

  1. Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. 2021-01-01 · Expand citations
  2. Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. 2020-02-28 · Expand citations
  3. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. 2019-08-01 · Expand citations
  4. Rapid-Acting Antidepressants. 2018-01-01 · Expand citations
  5. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. 2016-12-01 · Expand citations
  6. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
  7. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 2016-07-01 · Expand citations
  8. Concise Large-Scale Synthesis of Psilocin and Psilocybin, Principal Hallucinogenic Constituents of “Magic Mushroom” 2003-06-01 · Expand citations
  9. 10.1001/archpsyc.1994.03950030035004
  10. 10.1001/archpsyc.63.8.856
  11. 10.1002/0471264180.os080.26
  12. 10.1007/bf00433008
  13. 10.1007/pl00005481
  14. 10.1007/s00213-002-1154-7
  15. 10.1007/s00213-009-1500-0
  16. 10.1007/s00213-010-1834-7
  17. 10.1007/s00213-011-2277-5
  18. 10.1007/s00213-016-4389-4
  19. 10.1007/s002280100353
  20. 10.1007/s00406-020-01110-5
  21. 10.1016/0006-8993(84)91326-x
  22. 10.1016/0014-2999(90)90204-j
  23. 10.1016/0031-9384(92)90170-7
  24. 10.1016/j.biopsych.2006.11.017
  25. 10.1016/j.biopsych.2010.03.004
  26. 10.1016/j.euroneuro.2013.03.002
  27. 10.1016/j.euroneuro.2014.04.007
  28. 10.1016/j.euroneuro.2020.09.004
  29. 10.1016/j.jad.2014.12.057
  30. 10.1016/j.neuropharm.2016.03.038
  31. 10.1016/j.pbb.2006.07.019
  32. 10.1016/j.pbb.2020.173011
  33. 10.1016/j.tips.2009.09.002
  34. 10.1016/s0006-3223(99)00230-9
  35. 10.1016/s0166-4115(96)80059-8
  36. 10.1016/s0166-4115(97)80055-6
  37. 10.1016/s0166-4115(97)80056-8
  38. 10.1016/s0924-977x(96)00042-9
  39. 10.1016/s2215-0366(19)30292-5
  40. 10.1021/acs.oprd.9b00436
  41. 10.1037/0097-7403.7.1.18
  42. 10.1037/0097-7403.9.2.171
  43. 10.1037/a0024722
  44. 10.1038/s41380-021-01093-2
  45. 10.1038/s41467-020-20190-4
  46. 10.1057/978-1-137-40883-9_10
  47. 10.1093/schbul/sbx050
  48. 10.1097/00000542-198204000-00011
  49. 10.1097/00008877-199708000-00003
  50. 10.1097/01.fbp.0000189810.69425.89
  51. 10.1097/fbp.0b013e328334707a
  52. 10.1177/0269881106065859
  53. 10.1177/0956797611435817
  54. 10.1192/bjp.bp.105.015263
  55. 10.1371/journal.pone.0115374
  56. 10.7554/elife.11386

Cited by — these papers cite this paper (1)

  1. Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex 2026-06-01 · Expand citations